Adult ADHD medications in France — the honest overview (no marketing)

Who this page is for

You’ve been diagnosed with ADHD — or you’re approaching the moment where medication will come up — and you want to understand what can be offered to you, without going through anxious forums or sugar-coated pharma leaflets. This page does the overview. Each molecule has a dedicated, more detailed page — you’ll find the links at the bottom.

The point isn’t to push you toward or away from treatment. It’s to give you enough to have an honest conversation with your psychiatrist.

Overview — what’s available in France in 2026

In France, four main drug families can be used in adult ADHD:

Family	Molecule (brand)	Adult marketing authorisation (France)	Role
Classic stimulant	Methylphenidate (Ritaline, Concerta, Quasym LP, Medikinet LP)	Yes (extended-release)	First-line
Prodrug stimulant	Lisdexamfetamine (Elvanse Adulte)	Yes (since 2021)	Alternative first-line / after methylphenidate failure
Noradrenergic non-stimulant	Atomoxetine (Strattera)	Yes	Second-line / specific profiles
Alpha-2 agonist non-stimulant	Guanfacine extended-release (Intuniv)	No for adults (children only)	Off-label only
Antidepressants (bupropion, venlafaxine, atomoxetine-like)	—	No ADHD authorisation for adults in France	Comorbidity add-on, off-label for ADHD

Important: in France, initial prescribing is restricted to psychiatrists, neurologists and paediatricians. After stabilisation, your GP can renew, but the annual validation stays with the specialist ^[6] . Check with your doctor if you’re unsure who can do what in your case.

Methylphenidate — the workhorse

Indication and role

First-line for adult ADHD in France according to HAS ^[1] and international practice ^[10] . The reference meta-analysis (Cortese 2018, Lancet Psychiatry) ^[7] : superior to placebo with a medium effect size, tolerability similar to placebo in adults.

How it works — simple version

Methylphenidate blocks the reuptake of dopamine and noradrenaline in the synapses ^[8] . Translation: it doesn’t add neurotransmitters, it lets those already produced circulate a bit longer. The result, for those who respond: better attention recruitment, easier task initiation, fewer impulsive discharges.

French formulations

• Ritaline (IR, immediate release): 3-4 hours of action, useful for fine titration or end-of-day top-ups.
• Ritaline LP: 6-8 hours.
• Concerta LP (OROS): 10-12 hours, the longest action window available in France.
• Quasym LP / Medikinet LP: around 8 hours.
• Generics: Arrow, Biogaran, Mylan, Sandoz — pharmaceutical equivalence recognised, though some people subjectively report differences (worth discussing with your doctor if that’s your case).

Dose adjustment — the general idea

Gradual titration over 4 to 8 weeks, in weekly steps, aiming for the minimum effective dose. HAS and NICE recommend not exceeding authorised doses without strong clinical reason. No specific dosage here — it’s an individual clinical decision.

Side effects

Common (usually manageable): decreased appetite, sleep-onset insomnia if taken too late, headaches, dry mouth, mild nervousness, modest tachycardia (+5-10 bpm on average), rise in systolic blood pressure (+2-4 mmHg).

Less common but worth knowing: bruxism (teeth grinding), reduced libido, end-of-dose rebound, tics in predisposed individuals.

Serious — flag without delay: chest pain, unusual palpitations, fainting, unexplained shortness of breath, delusional thoughts / hallucinations, worsening suicidal thoughts, priapism, significant weight loss.

For detail and a nuanced read on long-term cardiovascular risk (Zhang 2024 vs Li 2024), see the detailed methylphenidate page.

Lisdexamfetamine (Elvanse Adulte) — the 2021 option

What it is

Lisdexamfetamine is a prodrug: an inactive molecule until the body converts it into dextroamphetamine. Marketed as Elvanse Adulte (Takeda). European adult marketing authorisation granted by the EMA ^[4] in 2021, available in France the same year ^[3] .

Why it’s a useful addition

Before 2021, France had no amphetamine available for ADHD adults — unlike the US (Adderall, Vyvanse) and several European countries. The arrival of Elvanse Adulte gave us a second first-line option, useful when methylphenidate isn’t effective enough or isn’t well tolerated.

How it works

Dextroamphetamine works by blocking the reuptake of dopamine and noradrenaline AND by triggering their presynaptic release — a broader mechanism than methylphenidate. Long duration (typically 10-13 hours) thanks to gradual prodrug metabolism.

Form and duration

Capsules 20, 30, 40, 50, 60, 70 mg. One morning dose. The long duration smooths out peaks-and-crashes, which makes it easier for some patients emotionally.

Side effects

Profile close to methylphenidate, with a few differences:

• Appetite suppression often more marked early on.
• Insomnia more frequent if taken after midday.
• Dry mouth sometimes more intense.
• Gentler “wearing off” at end of day (prodrug effect).
• Abuse potential theoretically higher (amphetamine), but limited by the prodrug form and oral route.

Contraindications and precautions are the same as for other stimulants.

Prescribing framework

Controlled substance, 28-day secure prescription, initial prescribing by psychiatrist / neurologist / paediatrician. Reimbursement: 65% by French public health insurance, chronic-condition status possible depending on file. Public price around €55-80/month depending on dose.

For detail, see the lisdexamfetamine page.

Atomoxetine (Strattera) — the non-stimulant route

What it is

A non-stimulant molecule that selectively targets the noradrenaline transporter ^[5] . No abuse potential. No typical rebound phenomenon. Standard prescription (not secure, not a controlled substance).

Role in practice

Alternative of choice when:

• Stimulants aren’t tolerated (major anxiety, stubborn insomnia, cardiovascular issues).
• Risk or history of substance addiction (cocaine, amphetamines, severe alcohol use).
• Patient preference for not taking a stimulant.
• Comorbid anxiety disorder or predominant tics.

What to know about efficacy

Slightly smaller average effect size than stimulants (Cortese 2018) ^[7] , but often a smoother benefit across the day. Onset of effect: 4 to 8 weeks — this isn’t a medication that kicks in within 30 minutes.

Form and dose

Capsules 10, 18, 25, 40, 60, 80 mg. Once-daily dosing (sometimes split). Gradual titration, weight-based at start.

Side effects

Common: initial fatigue (often transient), nausea, decreased appetite, dry mouth, ejaculation disorders / reduced libido (more marked than under stimulants for some).

Worth knowing: rare liver dysfunction, suicidal thoughts monitored in under-25s, hypertension and tachycardia monitored. Clinical and biological follow-up (baseline liver panel) recommended.

For detail, see the atomoxetine page.

Guanfacine (Intuniv) — at the margins, off-label for adults in France

French status

The French and European marketing authorisation for extended-release guanfacine (Intuniv) covers children and adolescents aged 6-17. For adults, prescribing is off-label (outside authorised indication).

When it can be discussed

Some trained psychiatrists propose off-label guanfacine for specific profiles: ADHD + significant anxiety + insomnia, mild hypertension, or after failure of other lines. Adult data exist (Biederman et al. 2019) ^[11] but remain less robust than for stimulants or atomoxetine.

What it implies

• Prescription under the doctor’s responsibility, not reimbursed in this indication.
• Hypotensive effect — interesting in some, contraindicated in others.
• Initial sedation is common.

If a doctor suggests adult guanfacine, ask: “What’s the clinical reasoning? What are you expecting compared to atomoxetine?” Check with your doctor — this section isn’t a green light to request an off-label prescription, just a reminder that it exists.

Antidepressants as add-ons

No ADHD marketing authorisation in France, but sometimes used as add-ons to the main treatment, especially with comorbidities (depression, anxiety, emotional instability). The most common in practice:

• Bupropion: effect on dopamine and noradrenaline, can have a small ADHD action. Not marketed as an antidepressant in France (available under the name Zyban for smoking cessation), so very little used for ADHD in France.
• Venlafaxine / duloxetine: noradrenergic, sometimes used with depression + ADHD. Modest ADHD effect, not their main indication.
• Atomoxetine itself was historically used as an “antidepressant” before being repositioned for ADHD — it’s the same molecule.

These choices are discussed case by case with the psychiatrist, based on the comorbidity picture.

Myths to dismantle

How to know if it’s working for you

The evaluation window

For a stimulant, the question “is it working?” applies after 4 to 6 weeks at stable dose. For atomoxetine, more like 6 to 10 weeks. Below that, you’re probably evaluating transient side effects, not the real response.

Keep an efficacy journal

A trained psychiatrist will probably ask you to note:

• Your ADHD symptoms rated 0 to 10 (attention, organisation, impulsivity, emotions) — before, then weekly.
• The concrete functional impact (managed to pay bills on time? finished my report without extreme procrastination? followed a conversation to the end?).
• Side effects (sleep, appetite, mood, energy, cardio).

This journal is your best dialogue tool with your doctor.

Dose adjustment

If it’s not working well enough or side effects are bothersome, don’t change anything without your doctor. Possible levers:

• Increase the dose gradually (within the authorised range).
• Change the formulation (IR to LP, or the other way round to cover specific moments).
• Shift the timing.
• Switch to another molecule.

When to switch molecules

Common reasons:

• Persistent and bothersome side effects after 6-8 weeks.
• No significant response at a correct dose after 6 weeks.
• Comorbidity that appears or changes (anxiety, insomnia, cardiovascular).
• Persistent shortages of the current molecule (France 2023-2026 saw several supply tensions).

A switch doesn’t mean the first treatment failed — individual response to ADHD medications varies hugely. Some people respond very well to methylphenidate and not to Elvanse; others the reverse.

Contraception, pregnancy, breastfeeding

A subject to systematically discuss with your doctor. Broad outline (to verify with a professional):

• Contraception: no major known interaction between stimulants / atomoxetine and standard hormonal contraceptives. Always confirm with your doctor based on your situation.
• Pregnancy: data are limited and stopping treatment is often recommended, but not automatic. Case-by-case decision, weighing benefit/risk. Don’t make this decision without a doctor.
• Breastfeeding: stimulants pass into breast milk in small amounts. Cautious position in France. To be re-discussed case by case.

Check with your doctor — this page isn’t a substitute for a dedicated consultation, especially on these topics.

The checklist before starting treatment

Indicative monthly cost (reimbursement included)

Treatment	Approx. public price	Remainder after 65% public insurance
Methylphenidate (Ritaline, Concerta, Quasym LP, generics)	€20-45/month	~€8-16 before top-up insurance
Lisdexamfetamine (Elvanse Adulte)	€55-80/month	~€20-30 before top-up insurance
Atomoxetine (Strattera)	€60-110/month	~€22-40 before top-up insurance
Guanfacine (off-label for adults)	€80-120/month	Not reimbursed for adults

Source: Vidal / ANSM databases, 2024-2025. Prices subject to change — verify with your pharmacist or on ameli.fr.

It took me 9 months to find the right molecule. Methylphenidate: too jittery. Elvanse: fine in the morning, disaster at night. I ended up on atomoxetine + half-dose Concerta. No one had told me you had to keep trying. Thankfully, my psychiatrist did.

Warning signs while on treatment

Takeaways

Go further

• Understand — what ADHD actually is
• Methylphenidate — the detailed page
• Lisdexamfetamine (Elvanse Adulte) — the detailed page
• Atomoxetine (Strattera) — the detailed page
• Managing side effects — practical guide
• ADHD medication shortages in France — what to do
• Preparing your first psychiatry consultation
• The diagnostic pathway
• Complementary therapies — CBT, DBT, coaching
• Everyday tools